Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation

Atrial fibrillation - dabigatran etexilate: review decision - April 2013 information

Atrial fibrillation - dabigatran etexilate: Appendix A decision paper presented to the Institute's Guidance Executive (PDF 195 KB)

Atrial fibrillation - dabigatran etexilate: review proposal - February 2013 information

Appendix A: provisional matrix of stakeholders (PDF 107 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 632 KB)

Atrial fibrillation - dabigatran etexilate: equality impact assessment - guidance development (PDF 79 KB)

Atrial fibrillation - dabigatran etexilate: appeal  information

Atrial fibrillation - dabigatran etexilate: appeal decision (PDF 170 KB)

Atrial fibrillation - dabigatran etexilate: appeal announcement information

Atrial fibrillation - dabigatran etexilate: appeal from NHS Salford

Atrial fibrillation - dabigatran etexilate: NHS Salford - appeal received (PDF 490 KB)

Atrial fibrillation - dabigatran etexilate: NHS Salford - initial scrutiny letter (PDF 78 KB)

Atrial fibrillation - dabigatran etexilate: NHS Salford - response to scrutiny letter (PDF 675 KB)

Atrial fibrillation - dabigatran etexilate: NHS Salford - final scrutiny letter (PDF 43 KB)

Atrial fibrillation - dabigatran etexilate: notice of appeal information

Atrial fibrillation - dabigatran etexilate: register to attend the appeal information

Atrial fibrillation - dabigatran etexilate: final appraisal determination information

Atrial fibrillation - dabigatran etexilate: final appraisal determination (PDF 259 KB)

Atrial fibrillation - dabigatran etexilate: response to consultee, commentator and public comments on the appraisal consultation document (ACD) (PDF 857 KB)

Atrial fibrillation - dabigatran etexilate: consultee and commentator comments on the ACD

Atrial fibrillation - dabigatran etexilate: AntiCoagulation Europe (ACE) comments on the ACD (PDF 57 KB)

Atrial fibrillation - dabigatran etexilate: Arrhythmia Alliance comments on the ACD (PDF 406 KB)

Atrial fibrillation - dabigatran etexilate: Atrial Fibrillation Association comments on the ACD (PDF 283 KB)

Atrial fibrillation - dabigatran etexilate: Bayer comments on the ACD (PDF 87 KB)

Atrial fibrillation - dabigatran etexilate: Boehringer Ingelheim comments on the ACD (PDF 337 KB)

Atrial fibrillation - dabigatran etexilate: Bristol Myers-Squibb & Pfizer comments on the ACD (PDF 174 KB)

Atrial fibrillation - dabigatran etexilate: British Cardiovascular Intervention Society comments on the ACD (PDF 69 KB)

Atrial fibrillation - dabigatran etexilate: Commissioning Support & Appraisal Service comments on the ACD (PDF 290 KB)

Atrial fibrillation - dabigatran etexilate: Department of Health comments on the ACD (PDF 63 KB)

Atrial fibrillation - dabigatran etexilate: Heart Rhythm UK comments on the ACD (PDF 21 KB)

Atrial fibrillation - dabigatran etexilate: NHS Salford comments on the ACD (PDF 279 KB)

Atrial fibrillation - dabigatran etexilate: Royal College of Nursing comments on the ACD (PDF 57 KB)

Atrial fibrillation - dabigatran etexilate: Royal College of Physicians comments on the ACD (PDF 285 KB)

Atrial fibrillation - dabigatran etexilate: comments on the ACD received from the public through the NICE website (PDF 331 KB)

Atrial fibrillation - dabigatran etexilate: ERG review of the manufacturer's resubmission (PDF 598 KB)

Atrial fibrillation - dabigatran etexilate: appraisal consultation

Atrial fibrillation - dabigatran etexilate: appraisal consultation document information

Atrial fibrillation - dabigatran etexilate: evaluation report

Atrial fibrillation - dabigatran etexilate: pre-meeting briefing (PDF 429 KB)

Atrial fibrillation - dabigatran etexilate: Evidence Review Group report (PDF 1.46 MB)

Atrial fibrillation - dabigatran etexilate: Evidence Review Group - factual accuracy check (PDF 143 KB)

Atrial fibrillation - dabigatran etexilate: Boehringer Ingelheim (PDF 4.38 MB)

Atrial fibrillation - dabigatran etexilate: clarification

Atrial fibrillation - dabigatran etexilate: NICE clarification letter (PDF 170 KB)

Atrial fibrillation - dabigatran etexilate: manufacturer response to the NICE clarification letter (PDF 715 KB)

Atrial fibrillation - dabigatran etexilate: patient group, professional group and NHS organisation submission statements

Atrial fibrillation - dabigatran etexilate: Arrhythmia Alliance (PDF 76 KB)

Atrial fibrillation - dabigatran etexilate: Clinical Leader of Thrombosis (CLOT) (PDF 60 KB)

Atrial fibrillation - dabigatran etexilate: Heart Rhythm UK (PDF 68 KB)

Atrial fibrillation - dabigatran etexilate: NHS Salford (PDF 50 KB)

Atrial fibrillation - dabigatran etexilate: Royal College of Nursing (PDF 70 KB)

Atrial fibrillation - dabigatran etexilate: Royal College of Pathologists and British Society for Haematology (PDF 218 KB)

Atrial fibrillation - dabigatran etexilate: South Asian Health Foundation (PDF 63 KB)

Atrial fibrillation - dabigatran etexilate: expert written personal statements

Atrial fibrillation - dabigatran etexilate: Laffan (PDF 131 KB)

Atrial fibrillation - dabigatran etexilate: Lip (PDF 100 KB)

Atrial fibrillation - dabigatran etexilate: Lovelock (PDF 117 KB)

Atrial fibrillation - dabigatran etexilate: Eaton (PDF 110 KB)

Atrial fibrillation - dabigatran etexilate: Jerrome (PDF 91 KB)

Atrial fibrillation - dabigatran etexilate: Institute's response to consultee and commentator comments on the provisional matrix (PDF 27 KB)

Atrial fibrillation - dabigatran etexilate: Institute's response to consultee and commentator comments on the draft scope (PDF 47 KB)

Atrial fibrillation - dabigatran etexilate: final matrix of consultees (PDF 34 KB)

Atrial fibrillation - dabigatran etexilate: final scope (PDF 27 KB)

Atrial fibrillation - dabigratran etexilate: draft scope April 2009 (PDF 31 KB)

Atrial fibrillation - dabigratran etexilate: provisional matrix April 2009 (PDF 34 KB)